open menu open menu


Extracorporeal Shockwave Therapy (ESWT) a revolutionary new way to treat erectile dysfunction
  • Uses low-intensity shockwaves to stimulate tissue repair and blood vessel growth4

  • Treats ED from the root cause

  • Improves overall blood flow to the penis

ESWT achieves a significant and long lasting improvement of erectile function in up to 70% of men, depending on severity and case history. Restore spontaneity to your love life and improve the quality of erection.


Vascular aging, and wear and tear of the blood vessels through injuries reduce blood flow in the penis.

Angiogenesis is the formation of new blood vessels. More blood vessels lead to better blood flow.

ESWT directly stimulates the penis prompting angiogenesis to take place, effects of the procedure are fast acting with measurable results within 6 sessions.

Before Treatment

Penile tissue during vascular dysfunction

After 2–3 Sessions

Secretion of angiogenic factors

After 5–6 Sessions

Enhanced angiogenesis in penile tissue

Before Treatment

Vascular deterioration due to a variety of factors lead to narrower blood vessels, preventing engorgement of the penis.

After 2–3 Sessions

Direct stimulation of the blood vessels promotes angiogenesis, which encourages the growth of new healthy blood vessels, improving blood flow in the penis.

After 5–6 Sessions

Blood vessels begin to be fully formed, enjoying long term effects of improved blood flow, encouraging natural erections.



Two Years Experience With Penile Low-Intensity Shock Wave Therapy for Erectile Dysfunction.

6 weeks after treatment, among the patient population, 85% experienced improved erectile function, with another 10% achieving significant improvement in erectile function. article/S1743-6095(17)30917-7/pdf


Low-Intensity Shockwave Therapy for Erectile Dysfunction: A Randomized Clinical Trial Comparing 2 Treatment Protocols and the Impact of Repeating Treatment. pubmed/29396020

Over 80% success rate in mild ED patients after 6 sessions

76% of patients showed significant improvement in erectile function, measured through IIEF-EF


Low-Intensity Extracorporeal Shock Wave Therapy for Severe Erectile Dysfunction in Poor Responders to Phosphodiesterase Type-5 Inhibitors: A Short-Term Prospective Study.

Out of 100% of patients suffering from severe ED and not seeing any results from PDE5i (common pill based medication), ESWT therapy was able to:

  • Restore normal erectile function in 17% of patients, without the use of pills
  • Enable 53% of patients to use PDE5i to achieve erectile function

https://www.eusupplements. S1569-9056(16)61116-8/pdf

  1. Giuliano F, Assaly-Kaddoum R, Laurin M, Bernabé J, Behr-Roussel D."981 - Low intensity shockwave therapy (Li-ESWT) delivered by Aries® improves erectile function and decreases cavernosal fibrosis of spontaneously hypertensive rats (SHR)."Eur Urol Suppl. 2018 Mar 1;17(2):e1384.
  2. Kalyvianakis D, Memmos E, Mykoniatis I, Kapoteli P, Memmos D, Hatzichristou D."Low-Intensity Shockwave Therapy for Erectile Dysfunction: A Randomized Clinical Trial Comparing 2 Treatment Protocols and the Impact of Rep eating Treatment." J Sex Med. 2018 Mar;15(3):334–45.
  3. Zewin T, El-Assmy A, Harraz A, Elsherbini A, Musa Z, Bayoumi A, et al."1115 Low-intensity extracorporeal shock wave therapy for severe erectile dysfunction in poor responders to phosphodiesterase type-5 inhibitors: A short-term prospective study." Eur Urol Suppl. 2016 Mar 1;15(3):e1115.
  4. Mild discomfort may be experienced in some cases, depending on the individual patient.

This website contains general information about medical conditions and treatments. The information is not advice and should not be treated as such. If you have any specific questions about any medical matter you should consult your doctor or other professional healthcare provider. Please see the medical disclaimer page for full details. This site is protected by copyright and trademark laws under U.S. and International law. Terms and Conditions. All rights reserved. ©2021 Dornier MedTech.

All rights reserved. ©2021 Dornier MedTech.
DMT530-022019-REV A EN